RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company's Medical Advisory Board

PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. Dr. Dritschilo is a renowned educator, inventor, translational scien

Related Keywords

New Jersey ,United States ,Anatoly Dritschilo ,Larry Perich ,Jerry Katzman ,Company Annual Report On Form ,Medstar Research Institute ,Company Medical Advisory Board ,Retinalgenix Technologies Inc ,Harvard Joint Center ,Lombardi Comprehensive Cancer Center ,University Of Pennsylvania ,National Academy Of Inventors ,National Capital Rehabilitation Hospital ,Medstar Georgetown University Hospital ,College Of Medicine New Jersey ,Department Of Radiation Medicine ,Georgetown University ,Georgetown University Hospital ,Genix Technologies ,Medical Advisory ,High Resolution Retinal Imaging ,Pharmaco Genetic Mapping ,Shuttle Pharmaceuticals Holdings ,Medical Director ,Interim Director ,Medstar Research ,National Academy ,Chemical Engineering ,Age Related Macular Degeneration ,Senior Consultant ,Fred Chasalow Phd ,Private Securities Litigation Reform Act ,Annual Report ,Ocular Diseases ,Company ,Systemic Diseases ,Ritschilo ,Development ,Remote Monitoring System ,Developing ,